Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial

John R. Petrie*, Nishi Chaturvedi, Ian Ford, Martijn C. G. J. Brouwers, Nicola Greenlaw, Therese Tillin, Irene Hramiak, Alun D. Hughes, Alicia J. Jenkins, Barbara E. K. Klein, Ronald Klein, Teik C. Ooi, Peter Rossing, Coen D. A. Stehouwer, Naveed Sattar, Helen M. Colhoun, REMOVAL Study Grp

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)597-609
Number of pages13
JournalThe Lancet Diabetes & Endocrinology
Volume5
Issue number8
DOIs
Publication statusPublished - Aug 2017

Keywords

  • INTIMA-MEDIA THICKNESS
  • GLYCEMIC CONTROL
  • ENDOTHELIAL FUNCTION
  • OF-VIEW
  • COMPLICATIONS
  • PROGRESSION
  • DEFICIENCY
  • MORTALITY
  • DISEASE
  • DESIGN

Cite this

Petrie, J. R., Chaturvedi, N., Ford, I., Brouwers, M. C. G. J., Greenlaw, N., Tillin, T., Hramiak, I., Hughes, A. D., Jenkins, A. J., Klein, B. E. K., Klein, R., Ooi, T. C., Rossing, P., Stehouwer, C. D. A., Sattar, N., Colhoun, H. M., & REMOVAL Study Grp (2017). Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial. The Lancet Diabetes & Endocrinology, 5(8), 597-609. https://doi.org/10.1016/S2213-8587(17)30194-8